Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures

Jolly, Meenakshi; Kazmi, Nazia; Mikolaitis, Rachel A.; Sequeira, Winston; Block, Joel A.

doi:10.1016/j.jaad.2012.08.035

Cited by 41 publications

(37 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This index, which accounts for lesional morphology as well as anatomic location, has since been validated by reliability testing for both dermatologists and rheumatologists [39]. A large study by Jolly et al further validated the CLASI tool, which has proven to be a valuable resource for research into CLE pathogenesis and treatment [40]. This tool is being used in many international studies and has been shown to be responsive to improvement in disease activity, as well as correlate with quality of life and a number of biomarkers [41-45].…”

Section: How Can We Properly Diagnose Cle?mentioning

confidence: 99%

Cutaneous lupus erythematosus: Diagnosis and treatment

Okon¹,

Werth²

2013

Best Practice & Research Clinical Rheumatology

255

257

View full text Add to dashboard Cite

Cutaneous lupus erythematosus encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several subtypes, including acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, and chronic cutaneous lupus erythematosus. Chronic cutaneous lupus erythematosus includes discoid lupus erythematosus, lupus erythematosus profundus, chilblain cutaneous lupus, and lupus tumidus. Diagnosis of these diseases requires proper classification of the subtype, through a combination of physical exam, laboratory studies, histology, antibody serology, and occasionally direct immunofluorescence, while ensuring to exclude systemic disease. Treatment of cutaneous lupus consists of patient education on proper sun protection along with appropriate topical and systemic agents. Systemic agents are indicated in cases of widespread, scarring, or treatment-refractory disease. In this review, we discuss issues in classification and diagnosis of the various subtypes of CLE, as well as provide an update on therapeutic management.

show abstract

Section: How Can We Properly Diagnose Cle?mentioning

confidence: 99%

Cutaneous lupus erythematosus: Diagnosis and treatment

Okon¹,

Werth²

2013

Best Practice & Research Clinical Rheumatology

255

257

View full text Add to dashboard Cite

show abstract

“…The CLASI™ can be used to follow patients in a specialty clinic, but its main role is for cohort or therapeutic studies. The CLASI™ has been validated against physician- and patient-reported outcomes, including measures of cutaneous damage [5] and quality of life [4]. The latter is especially important to consider in the assessment of these patients, as individuals with CLE have demonstrated a poorer quality of life than those with other common conditions affecting the skin [6] across multiple geographic populations [7].…”

Section: Evaluation Of Disease Severitymentioning

confidence: 99%

Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects

Chang

Werth

2016

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Introduction Treatment and prevention are of critical importance in patients with cutaneous lupus erythematosus (CLE), as the disease can have a devastating effect on patient well-being and quality of life. Areas Covered We conducted a selective search of the PubMed database for articles published between December 2010 and November 2015. This review encompasses both non-pharmaceutical (photoprotection, smoking cessation, drug withdrawal, and vitamin D replacement) and pharmaceutical (topicals, antimalarials, immunosuppressives, biologics, etc.) interventions used in the treatment of CLE. Expert Commentary Recent work has expanded our understanding of established therapies as well as introduced new treatments for consideration, though existing medications still prove inadequate for a subset of patients. Changes in trial design may help to alleviate this issue.

show abstract

“…All subtypes of CLE may be evaluated according to the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), a tool developed and validated to score CLE on the basis of disease activity (the presence of erythema, scale, and hypertrophy) as well as damage (dyspigmentation, scarring, atrophy, and panniculitis) (2). Its manifestations are morphologically diverse and can be characterized as acute, subacute, or chronic.…”

Section: Introductionmentioning

confidence: 99%

Review of treatment for discoid lupus erythematosus

Garza-Mayers

McClurkin

Smith

2016

Dermatologic Therapy

View full text Add to dashboard Cite

Discoid lupus erythematosus (DLE) is a chronic cutaneous disease characterized by inflammatory plaques that, in the absence of prompt diagnosis and treatment, may lead to disfiguring scarring and skin atrophy. However, there is limited evidence for which treatments are most effective. Currently, no medications have been approved specifically for the treatment of DLE. Many of the drugs described in the literature were developed for use in other immune disorders. This review will summarize current therapeutic options for DLE and their supporting evidence with discussion of prevention, topical measures, physical modalities, and systemic therapies, including newer potential therapies.

show abstract

Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures

Cited by 41 publications

References 14 publications

Cutaneous lupus erythematosus: Diagnosis and treatment

Cutaneous lupus erythematosus: Diagnosis and treatment

Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects

Review of treatment for discoid lupus erythematosus

Contact Info

Product

Resources

About